🟢 Strong Evidence
A randomised controlled trial published in The Lancet Regional Health – Europe has found that immunoadsorption therapy provides no significant benefit for patients with post-COVID syndrome. The crossover trial, conducted across multiple centres in Germany, compared the blood filtration treatment against sham procedures in 60 patients with persistent COVID-19 symptoms.
Key takeaways
- Immunoadsorption showed no significant reduction in long COVID symptom burden compared to sham treatment
- 60 patients with post-COVID syndrome participated in the randomised crossover trial across German centres
- Results challenge the rationale for using blood filtration therapies in long COVID treatment protocols
Study at a Glance
| Source | The Lancet Regional Health – Europe |
| Study type | Randomised sham-controlled crossover trial |
| Sample size | N = 60 |
| Population | Adults with post-COVID syndrome |
| Country | Germany |
Treatment Response in Post-COVID Syndrome Trial
Symptom burden reduction comparison between treatments
Source: The Lancet Regional Health – Europe, 2026 | Georgian Medical Journal News
Trial Design Addresses Treatment Uncertainty
The German research team designed a crossover trial to test whether immunoadsorption, a blood filtration technique that removes antibodies and immune complexes, could alleviate post-COVID syndrome symptoms. According to the study authors in The Lancet Regional Health – Europe, the treatment was hypothesised to work by removing potentially harmful autoantibodies that some researchers believe contribute to long COVID pathophysiology.
The crossover design allowed each patient to serve as their own control, receiving both active immunoadsorption treatment and a sham procedure in random order. This approach, recommended by WHO guidance on post-COVID condition research, helps eliminate patient-to-patient variability that can confound results.
Primary Endpoint Shows No Significant Difference
The trial’s primary outcome measured changes in symptom burden using validated assessment scales for post-COVID syndrome. Researchers found no statistically significant difference between immunoadsorption and sham treatment sessions in reducing overall symptom severity.
This finding aligns with recent research highlighting the complexity of long COVID pathophysiology, as documented in studies published in PubMed’s long COVID literature. The results suggest that simple antibody removal may not address the multisystem nature of post-COVID syndrome, which affects an estimated 65 million people worldwide according to WHO estimates.
Implications for Clinical Practice
The negative results carry important implications for clinicians treating patients with persistent COVID-19 symptoms. Immunoadsorption procedures are resource-intensive, requiring specialised equipment and trained personnel, while carrying potential risks including blood loss and infection.
Dr. researchers noted in their discussion that the findings do not rule out all immune-mediated therapies for long COVID, but suggest that non-specific antibody removal approaches may be ineffective. This adds to growing evidence that targeted therapeutic approaches may be necessary for this heterogeneous condition.
Research Context and Future Directions
The study represents one of the first rigorous trials testing blood filtration therapies for post-COVID syndrome, addressing a treatment approach that some centres had begun offering despite limited evidence. The US Centers for Disease Control and Prevention has emphasised the need for evidence-based approaches to long COVID treatment.
Future research directions suggested by the authors include investigating more targeted immunomodulatory approaches and identifying biomarkers that might predict treatment response in specific patient subgroups. These findings underscore the importance of rigorous clinical trials in evaluating experimental treatments for this emerging condition.
Immunoadsorption therapy showed no significant benefit over sham treatment in reducing symptom burden among 60 patients with post-COVID syndrome
— Study authors, German research consortium (The Lancet Regional Health – Europe, 2026)
What this means
Frequently asked questions
What is immunoadsorption therapy?
Immunoadsorption is a blood filtration procedure that removes antibodies and immune complexes from the bloodstream. It requires specialised equipment and is typically used for certain autoimmune conditions.
Why was this treatment tested for long COVID?
Some researchers hypothesised that autoantibodies produced after COVID-19 infection might contribute to persistent symptoms. The theory was that removing these antibodies could improve patient outcomes.
What are the current evidence-based treatments for long COVID?
Current management focuses on symptom-specific approaches including graded exercise therapy, cognitive rehabilitation, and medications for specific symptoms like fatigue and brain fog, as recommended by clinical guidelines.
The negative trial results reinforce the importance of rigorous evidence standards in long COVID treatment development. As the global medical community continues investigating this complex condition, studies like this provide crucial guidance for clinicians and patients navigating treatment decisions. The research underscores that effective long COVID therapies will likely require precision approaches targeting specific disease mechanisms rather than broad immunomodulatory interventions.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
